Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Johnson & Johnson
Biotech
J&J drops phase 2 dengue candidate in latest shift from vaccines
Johnson & Johnson’s deprioritization of its infectious disease pipeline has claimed another victim in the form of its dengue virus vaccine mosnodenvir
James Waldron
Oct 4, 2024 10:14am
Trispecific antibody one-ups Tecvayli in myeloma mouse study
Sep 17, 2024 3:38pm
J&J consolidates medtech brands under single banner
Sep 10, 2024 10:30am
J&J ordered to pay $1B over fallout from Auris robotics deal
Sep 5, 2024 4:10pm
J&J files for FDA approval of $6.5B autoimmune drug
Aug 29, 2024 8:57am
Addex stock rises after Indivior offers up to $300M for compound
Aug 27, 2024 10:50am
